INTRODUCTION
Stress-stimuli such as irradiation, TNFα, lipopolysaccharide, and some chemotherapy drugs such as doxorubicin mediate apoptosis by generation of the lipid second messenger, ceramide (1) (2) (3) (4) . We have recently shown that another stress response, endothelial anoikis (apoptosis resulting from the loss of matrix-adhesion) is also associated with increased ceramide (5) . Ceramide can be generated by hydrolysis of membrane sphingomyelin by acid and/or neutral sphingomyelinase and via activation of the de novo ceramide synthesis pathway, both of which can promote apoptosis (1, 2, 4, (6) (7) (8) (9) (10) (11) . In light of the anti-endothelial effects of 4-HPR, its potential for antiangiogenic activity (14, 15) , and the role of ceramide as an important mediator of endothelial cell apoptosis (5,22-24),
we were interested in the role of ceramide signaling in mediating the anti-endothelial effect of 4-HPR. In the work reported here we demonstrate that 4-HPR induces a caspase-dependent endothelial apoptosis. We also show that 4-HPR increased endothelial cell ceramide by stimulation of de novo synthesis and that de novo generated ceramide has a causal role in
4-HPR-mediated apoptosis of human brain microvascular endothelial cells (human BMEC).
Lastly, we establish that ceramide functions upstream of caspases in the ordering of ceramide and caspases in endothelial cells. These results provide the first evidence for endothelial apoptosis by 4-HPR, and show that activation of the ceramide pathway is required for this apoptosis, thus presenting a molecular mechanism for the anti-angiogenic effects of 4-HPR. At the end of incubation adherent and detached cells were trypsinized, combined, and washed with PBS (4ºC). Total cellular lipids were extracted using equal volumes of methanol/2% acetic acid (v/v), water, and chloroform. After phase separation by centrifugation, the lower phase 
Reagents. 4-HPR was kindly provided by

RESULTS
4-HPR was cytotoxic to endothelial cells. As only one of two reports found 4-HPR to be
cytotoxic to endothelial cells, we determined the cytotoxicity of 4-HPR in human BMEC (Fig. 1 ). 
4-HPR was
4-HPR increased endogenous ceramide in endothelial cells. Ceramide is thought to
mediate endothelial apoptosis by stress stimuli (5, (22) (23) (24) , and exogenous C 2 -ceramide itself can induce endothelial apoptosis (5). Since we observed that 4-HPR induced apoptosis in endothelial cells, we determined whether this was associated with increased ceramide. 4-HPR effectively increased ceramide levels in human BMEC (Fig. 3) as well as in bovine TBMEC and HUVEC (Table 1 ). In the human BMEC mean ceramide increase was 5.25-fold ± 0.72 following 17 h incubation with 5 µM 4-HPR (n=12 experiments in triplicate, p<0.001). The increase in ceramide was observed as early as 4-8 h from the start of exposure to 4-HPR, before cytotoxicity or apoptosis could be detected, and continued to increase up to 24 h ( Fig. 3B-C) . A decrease in several unidentified faster-and slower-migrating lipid bands was observed in parallel to the increase in [ 3 H]ceramide (Fig 3C) . While it is possible that some of these are the lipids that contribute to the increase in ceramide (higher Rf in particular), it is difficult to evaluate the origin due to the large amount of radioactivity. FBS was included in the medium (Table 1 ). These data indicate that 4-HPR induced generation of ceramide in endothelial cells.
4-HPR stimulated de novo ceramide synthesis. Sphingomyelinase activation has been
thought to be the main pathway for ceramide generation in apoptosis following stress stimuli (1-4). However, later reports demonstrate that some stimuli can induce apoptosis via de novoceramide synthesis (6, 8, 10) . To determine which of these pathways was activated by 4-HPR in human BMEC we first examined whether 4-HPR-induced ceramide formation could be suppressed by inhibitors of de novo ceramide synthesis (Fig. 4) . Fumonisin B 1 (25 µM), an inhibitor of ceramide synthase, potently inhibited ceramide generation in endothelial cells exposed to 4-HPR (Fig. 4A) . Similarly, L-cycloserine (30 µM) and myriocin (0.05 µM), both inhibitors of the rate-limiting enzyme in the de novo ceramide synthesis pathway, serine palmitoyltransferase (SPT)(10), potently suppressed the 4-HPR-induced generation of ceramide ( Fig. 4B-C) . In order to more directly demonstrate the stimulation of de novo ceramide synthesis by 4-HPR, we measured activity of SPT in microsomes isolated from endothelial cells that had been exposed to the drug or to vehicle control (Fig. 4C) . Activity of SPT in absence of 4-HPR was 29.8 ± 0.2 pmol/mg protein/min, and increased by 1.75-fold after 2 h incubation with 10 µM 4-HPR (Fig. 4C) , confirming stimulation of de novo ceramide synthesis by 4-HPR. By 6 h of incubation with 4-HPR, SPT activity returned to baseline levels (Fig. 4C) (Fig. 5A) . Incubation with desipramine, a nonspecific inhibitor of sphingomyelin hydrolysis, starting 2 h before addition of 4-HPR, did not alter sphingomyelin levels in the presence of 4-HPR, further suggesting that 4-HPR did not activate sphingomyelinase (Fig. 5A ).
Under these conditions there was also no change in levels of cellular glucosylceramide in the presence of 4-HPR (Fig. 5C ). Interestingly, despite the removal of the remaining exogenous (Fig. 5B) . The increase in ceramide was not inhibited by desipramine (Fig. 5B) , further supporting that sphingomyelinase activation did not contribute to the 4-HPR-induced ceramide increase.
Inhibition of 4-HPR-induced ceramide generation suppressed endothelial apoptosis.
To determine whether activation of de novo ceramide synthesis has a causal role in 4-HPR-induced endothelial apoptosis we examined whether suppression of the increase in ceramide could prevent 4-HPR-induced apoptosis ( (Fig. 6A-B) . These data provide evidence for a causal role of 4-HPR-induced de novogenerated ceramide in endothelial apoptosis.
4-HPR-induced ceramide increase was independent of caspase activation in endothelial
cell apoptosis. To determine whether 4-HPR-induced apoptosis in BMEC was mediated by caspases, we examined whether apoptosis could be inhibited by caspase inhibitors. When human BMEC were incubated with the pan-caspase inhibitor, BOC-D-FMK, and exposed to 4-HPR, apoptosis was inhibited to baseline levels compared to control cells (Fig 7A-C) . Z-VAD- (Fig. 7D) . While BOC-D-FMK effectively inhibited 4-HPR-induced apoptosis ( Fig. 7A-C) , it had no effect on the 4-HPR-induced ceramide increase in human BMEC (Fig. 7D) . Similar results were obtained using bovine TBMEC (data not shown). These data place ceramide upstream of caspases in 4-HPR-induced endothelial apoptosis. Collectively, these data provide evidence for a signaling role for ceramide in 4-HPR-mediated endothelial apoptosis. Fenretinide caused no detectable sphingomyelin hydrolysis (Fig. 5) . Additionally, sphingomyelin and ceramide levels in 4-HPR treated cells were not altered by desipramine ( Our results further show that fumonisin B 1 efficiently suppressed the 4-HPR-mediated increase in endothelial ceramide, in parallel to prevention of the associated apoptosis ( Fig. 4 and   6 ). This demonstrates a causal role for ceramide in 4-HPR-mediated endothelial apoptosis. This Taken together, our study establishes a causal role for de novo-generated ceramide in the molecular mechanism of 4-HPR-induced endothelial apoptosis, and supports examination of 4-HPR as part of a combined antiangiogenic and anti-tumor approach to cancer therapy. A. 
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